Lookup NU author(s): Dr Ilse Pienaar,
Dr Joanna Elson,
Dr Claudia Racca,
Dr Glyn Nelson,
Professor Doug Turnbull,
Dr Christopher Morris
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Cholinergic neuronal loss in the pedunculopontine nucleus (PPN) associates with abnormal functions, including certain motor and non-motor symptoms. This realization has led to low-frequency stimulation of the PPN for treating Parkinson’s disease (PD) patients refractory to other treatment modalities. However, the molecular mechanisms underlying PPN neuronal loss and the therapeutic substrate for the clinical benefits following PPN stimulation remain poorly characterized, hampering progress towards designing more efficient therapies aimed at restoring the PPN’s normal functions during progressive Parkinsonism. Here we investigated post-mortem pathological changes in the PPN of PD cases. Our study detected a loss of GABAergic and glycinergic neurons, with an even more pronounced loss of cholinergic neurons, accompanied by altered somatic cell size affecting the remaining neurons of all neuronal subtypes studied here. Since studies showed that mitochondrial dysfunction exists in sporadic PD and in PD animal models, we investigated whether altered mitochondrial composition exists in the PPN. A significant upregulation of several mitochondrial proteins was seen in GABAergic and glycinergic neurons; however, cholinergic neurons revealed downregulation of the same proteins. Our findings suggest an imbalance in the activity of key neuronal subgroups of the PPN in PD, potentially due to abnormal inhibitory activity and altered cholinergic outflow.
Author(s): Pienaar I-S, Elson JL, Racca C, Nelson G, Turnbull DM, Morris CM
Publication type: Article
Publication status: Published
Journal: American Journal of Pathology
Print publication date: 04/10/2013
ISSN (print): 0002-9440
ISSN (electronic): 1525-2191
Altmetrics provided by Altmetric